Literature DB >> 29512752

MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA.

Shijuan Zhan1, Chunfeng Wang2, Fangqing Yin3.   

Abstract

Non-small cell lung cancer (NSCLC) is a primary sub-type of lung cancer with a high incidence rate and poor prognosis. The primary therapeutic treatment for NSCLC is chemotherapy, which is considered to be ineffective and excessively toxic. Novel therapeutic methods, particularly molecular targeted therapy, have attracted considerable attention. MicroRNAs (miRs) are reported to be potential biomarkers and targeted agents with roles in various types of tumors. Herein, the present study presented the observation of aberrant low expression of miR‑29c and associated overexpression of vascular endothelial growth factor A (VEGFA) in NSCLC tumor tissues. The effects of miR‑29c upon NSCLC tumor progression, including cell proliferation and cellular apoptosis, were investigated. The possible regulatory mechanism of action of miR‑29c on its direct target VEGFA and the phosphatidylinositol 3‑kinase (PI3K)/RAC‑α serine/threonine‑protein kinase (Akt) signaling pathway was examined using multiple methods, including reverse transcription-quantitative polymerase chain reaction analysis, dual luciferase assay and western blot analysis. The results demonstrated that miR‑29c expression was downregulated in NSCLC tumor tissues compared with normal tissues. A marked negative correlation in the expression of miR‑29c and VEGFA was observed in clinical NSCLC tissues and cultured NSCLC cells. Overexpression of miR‑29c may inhibit cell proliferation and accelerate the cellular apoptosis rate of NSCLC tumor cells. Furthermore, the overexpression of miR‑29c was demonstrated to be able to downregulate the expression levels of VEGFA and PI3K/Akt signaling pathway‑associated proteins. The results of the present study suggested that miR‑29c might regulate NSCLC tumor progression by targeting VEGFA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29512752     DOI: 10.3892/mmr.2018.8678

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

Review 1.  Prediction of Genes Involved in Lung Cancer with a Systems Biology Approach Based on Comprehensive Gene Information.

Authors:  Shahram Parvin; Hamid Sedighian; Ehsan Sohrabi; Mahdieh Mahboobi; Milad Rezaei; Dariush Ghasemi; Ehsan Rezaei
Journal:  Biochem Genet       Date:  2021-12-02       Impact factor: 2.220

2.  MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway.

Authors:  Junlei Han; Jianping Hu; Fang Sun; Hongzhi Bian; Bingxiang Tang; Xiang Fang
Journal:  Mol Cell Biochem       Date:  2020-10-30       Impact factor: 3.396

3.  Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer.

Authors:  Xia Yang; Qiuhong Zhang; Ming Zhang; Wenmei Su; Zhuwen Wang; Yali Li; Jie Zhang; David G Beer; Shuanying Yang; Guoan Chen
Journal:  Int J Biol Sci       Date:  2019-06-10       Impact factor: 6.580

4.  Long noncoding RNA TUG1 upregulates VEGFA to enhance malignant behaviors in stomach adenocarcinoma by sponging miR-29c-3p.

Authors:  Yanzhao Jin; Jiaqing Cao; Xiaoyun Hu; Hua Cheng
Journal:  J Clin Lab Anal       Date:  2021-11-11       Impact factor: 2.352

5.  miR-210-3p Promotes Lung Cancer Development and Progression by Modulating USF1 and PCGF3.

Authors:  Qian Chen; Hongyu Zhang; Jianyin Zhang; Le Shen; Jing Yang; Yan Wang; JinXiu Ma; Bing Zhuan
Journal:  Onco Targets Ther       Date:  2021-06-09       Impact factor: 4.147

Review 6.  The Impact of lncRNAs and miRNAs on Apoptosis in Lung Cancer.

Authors:  Soudeh Ghafouri-Fard; Amin Aghabalazade; Hamed Shoorei; Jamal Majidpoor; Mohammad Taheri; Majid Mokhtari
Journal:  Front Oncol       Date:  2021-07-21       Impact factor: 5.738

7.  MicroRNA-326 impairs chemotherapy resistance in non small cell lung cancer by suppressing histone deacetylase SIRT1-mediated HIF1α and elevating VEGFA.

Authors:  Jinying Wei; Guangping Meng; Jing Wu; Ying Wang; Qiang Zhang; Ting Dong; Jin Bao; Chunyan Wang; Jie Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.